Use of continuous subcutaneous growth hormone-releasing hormone (GHRH (1-29)NH2) infusions to augment growth hormone secretion and to promote growth.

Acta paediatrica Scandinavica. Supplement1989PMID: 2546369

Plain Language Summary

Eight children with partial growth hormone insufficiency were treated with continuous subcutaneous GHRH infusions, and all showed increased growth hormone secretion and improved growth velocity after three to six months of therapy. The study built on earlier adult data showing no desensitization during continuous GHRH delivery, confirming that this approach works in children as well. These results support the development of sustained-release GHRH preparations as a potential alternative to growth hormone injections for treating growth hormone-deficient children.

Abstract

It has previously been shown that an 8-day continuous subcutaneous infusion of GHRH (1-29)NH2 in adult males augments growth hormone (GH) secretion with no evidence of desensitization of the response. The present report details the results of treatment with continuous subcutaneous infusions of GHRH (1-29)NH2 in eight children aged 6-9 years with partial GH insufficiency. All the children showed augmentation of GH secretion and an increase in growth velocity after 3 and 6 months of therapy.

Authors

Brain, C; Hindmarsh, P C; Pringle, P J; Brook, C G